88 results about "Pancrelipase" patented technology

Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 9% or less or 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 25%, about 20%, about 15% or about 10% after six months of accelerated stability testing and the titer level of a viral contaminant present in the pancreatin is at least about 1000 times less than the titer level of the viral contaminant present in a preparation from which the pancreatin is obtained.

Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and / or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

The invention provides microcapsule fatty powder capable of increasing content of omega3-enriched meat egg milk and a preparation method of the microcapsule fatty powder. The microcapsule fatty powder capable of increasing the content of the omega3-enriched meat egg milk comprises a water soluble wall material and an omega3-containing fat core material embedded in the wall material, wherein the water soluble wall material is at least one of dextrin, water soluble syrup, whey powder and chitosan, and then is mixed with starch paste, and thus the microcapsule fatty powder is obtained; the omega3-containing fat core material is at least one of linseed oil, deep sea fish oil and algal oil and is prepared by mixing a compound emulsifier with sodium stearoyl lactate. The microcapsule fatty powder capable of increasing the content of the omega3-enriched meat egg milk can be combined at small intestines and pancrelipase easily, the digestion absorption utilization rate of fat containing omega3 is greatly increased, and the fatty powder capable of increasing the content of the omega3-enriched meat egg milk is resistant to oxidation and easy to store and can not be oxidized or become acid, and thus the content of omega3 is guaranteed.

The invention belongs to the technical field of medicaments, and in particular relates to application of isopentene group flavonoid compound used as a pancreatic lipase inhibitor. The flavonoid compound has the following structural formula and has a chemical name of: (E)-2-(2,4-dihydroxy phenyl)-5,7-dihydroxy-3-(3-methyl-2-butenyl)-6-(3-methy-l-butenyl)-4H-chromene-4-ketone, and can be extracted from artocarpus nitidus. Pancreatic lipase activity tests and experiments of weight loss action in animals prove that the compound has obvious pancreatic lipase inhibitory activity and weight loss action, can be taken as the lead compound for developing novel medicaments for preventing or curing obesity and related metabolic diseases, and also can be used for preparing the medicaments for preventing and curing clinically common multiple obesity and the related metabolic disease.

The invention provides a method for preparing biodiesel from immobilized lipase catalyzed pistacia chinensis bunge. The method is characterized in that the biodiesel is prepared by transesterification reaction of immobilized lipase catalyzed pistacia chinensis bunge which takes natural fiber-ramie as a vector and methanol. According to the invention, immobilized lipase can be recovered after esterification reaction and then continuously and repeatedly used thirteen times, and the activity maintaining rate of lipase is larger than 80.0%, thereby improving the utilization of lipase and reducingthe product cost resulting from lipase.

It is an object of the present invention to provide a dry analytical element for pancreatic lipase analysis having high selectivity with respect to pancreatic lipase, whose multianalyte correlation has been improved. The present invention provides a dry analytical element for measurement of pancreatic lipase contained in a body fluid, which comprises at least one development layer and / or reagent layer containing diglyceride or triglyceride of long-chain alkyl fatty acid having 12 to 22 carbon atoms, monoglyceride lipase, and a glycerine measurement reagent, wherein the development layer and / or the reagent layer comprise two or more types of anionic surfactants and at least one type of the anionic surfactant is alkylarylsulfonate.

The subject invention features compounds having the structure: wherein X is O, S, CH2 or NR5; Y is O or S; R1 is H, substituted or unsubstituted C1-C15 alkyl, C1-C8 alkylaryl, —C(O)OR4, —C(O)NR4R5, —CR6R6′OR4, —CR6R6′OC(O)R4, —CR6R6′OC(O)NHR7, —C(O)NR10R11, —C(O)NR8R9NR8R9, —N(R5)C(O)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain C1—C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, —CH2-aryl, aryl —C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6′ are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1H-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.

The invention provides meroganocochlearin which is separated from an ethyl acetate layer of Ganoderma cochlear and is novel in structure, a pharmaceutical composition which takes the meroganocochlearin as an active ingredient, a preparation method of the pharmaceutical composition and application thereof in pharmacy. Through in vitro experiment research, the meroganocochlearin can effectively inhibit activity of alpha-glucosidase and pancrelipase, and therefore can be used for treating diabetes and obesity and used as health-care functional food.

The invention provides application of a ginkgo biflavonoid compound in the preparation of slimming medicines and / or sliming medicine compositions. The ginkgo biflavonoid compound has the advantages that the activity of pancreatic lipase can be effectively inhibited, and the IC50 of inhibited pancreatic lipase is 2.90mum to 12.78mum; especially, the oral dose of the ginkgo biflavonoid is 4.5 to 12.5mg, the local exposure amount in the gastrointestinal system can reach 2.27 to 7.67mum, and the inhibiting constant is higher than the inhibiting constant (Ki=0.81mum) of the ginkgo biflavonoid on the pancreatic lipase, which indicates that the in-vitro medicine exposure concentration of the ginkgo biflavonoid can inhibit the pancreatic lipase at high efficiency, and further improve the digestionand absorption of lipid in the human body; the raw materials are easy to obtain, the safety is high, the extracting and preparation technologies are simple, the yield rate is high, and the like; a novel medicine source is provided for the preventing and controlling on the fat, and the good application prospect is realized in the preparation of the slimming medicines.

The invention discloses an anti-obesity peptide and application thereof, the amino acid sequences of five peptides are respectively RGGFLLAMVRAP, QSAFLHVMY, FLLWAAL, WLTAMLEWR and WYFPGR, and the peptide provided by the invention is synthesized by using a polypeptide synthesizer and adopting a solid-phase synthesis method. In-vitro activity detection shows that the 50% inhibition concentration of the five peptides to pancreatic lipase is within the range of 5.36-477.24 mu M. Under the concentration of 200 [mu] M, the content of triglyceride TG in 3T3-L1 cells can be reduced from 1.06 + / -0.06 mmol / gprot to 0.17 + / -0.02 to 0.69 + / -0.01 mmol / gprot by the five peptides. The invention provides five synthetic peptides with potential in-vitro anti-obesity activity, which can be applied to the field of biological pharmacy.